Akyüz Filiz, Beşişik Fatih, Pinarbaşi Binnur, Demir Kadir, Kaymakoğlu Sabahattin Tolga, Cakaloğlu Yilmaz, Sever Mehmet Sükrü, Okten Atilla
Department of Gastroenterohepatology, Istanbul University, School of Medicine, Istanbul.
Turk J Gastroenterol. 2009 Dec;20(4):243-6. doi: 10.4318/tjg.2009.0020.
BACKGROUND/AIMS: We aimed to determine the quality of life in treated and untreated hemodialysis patients with chronic hepatitis C virus infection.
Ninety-five chronic renal failure patients with positive antiHCV/HCV-RNA were enrolled in this prospective study. All patients were questioned using the Short Form-36 (SF-36) health survey to evaluate life quality after the treatment. Fifty-five (ALT>1.5 ULN) were treated with interferon-alpha-2b [3MU/tiw, sc, 6 (30 patients) and 12 (25 patients) months], and 40 (11 renal transplanted) were untreated. Fifteen patients had renal transplantation in a mean of 24.6+/-12.5 months after interferon-alpha treatment.
The mean age of the patients was 37+/-10 years, and 58 were male. The mean durations of hemodialysis and renal transplantation were 6.4+/-3.8 and 5.9+/-4.6 years, respectively. Interferon treatment had a negative effect on general health perception, physical activity and anxiety about the disease (p<0.05) when compared with the untreated patients. General health perception scores were positively slightly increased in interferon responder patients (p>0.05). General health and physical activity were better in transplanted patients than patients undergoing hemodialysis (p<0.05).
General health perception slightly increased positively in interferon responder patients. However, general health perception and physical activity were affected negatively by interferon treatment in the whole group analysis. Renal-transplanted patients have a better life quality compared with those on hemodialysis.
背景/目的：我们旨在确定接受治疗和未接受治疗的慢性丙型肝炎病毒感染血液透析患者的生活质量。
95例抗丙型肝炎病毒/丙型肝炎病毒核糖核酸呈阳性的慢性肾衰竭患者纳入了这项前瞻性研究。所有患者均接受简短健康调查问卷36（SF - 36）的询问，以评估治疗后的生活质量。55例（丙氨酸转氨酶>1.5倍正常上限）患者接受了α - 2b干扰素治疗[3MU/每周三次，皮下注射，6个月（30例患者）和12个月（25例患者）]，40例（11例接受肾移植）未接受治疗。15例患者在α - 干扰素治疗后平均24.6±12.5个月接受了肾移植。
患者的平均年龄为37±10岁，男性58例。血液透析和肾移植的平均持续时间分别为6.4±3.8年和5.9±4.6年。与未接受治疗的患者相比，干扰素治疗对总体健康感知、身体活动和对疾病的焦虑有负面影响（p<0.05）。在干扰素应答患者中，总体健康感知评分略有正向增加（p>0.05）。接受肾移植患者的总体健康和身体活动状况优于接受血液透析的患者（p<0.05）。
在干扰素应答患者中，总体健康感知略有正向增加。然而，在全组分析中，干扰素治疗对总体健康感知和身体活动有负面影响。与接受血液透析的患者相比，接受肾移植的患者生活质量更好。
